Benchmark on Monday started coverage of Dexcom with a Buy rating and a $77 price target, arguing the medical technology company is on track to expand margins meaningfully over the next two years as it ...
EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the publication of a ...
The company will unveil Dexcom Smart Basal*, a new integrated titration module designed to make basal insulin initiation and management easier† for users, which is currently under FDA and CE mark ...
Tuesday, the FDA approved DexCom Inc’s (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM). The Dexcom Stelo Glucose Biosensor System is ...
Best Buy plans to start selling continuous glucose monitors in the next few weeks, in the tech retailer’s first foray into prescription-based medical device sales. The company plans to sell the Dexcom ...
Hosted on MSN
Illumina and DexCom lift 2026 outlook after Q1 beats
Illumina and DexCom raised or reaffirmed 2026 guidance after stronger-than-expected first-quarter results. Illumina beat revenue and earnings forecasts on robust clinical markets, product placements, ...
VIENNA--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results